Company
Every investor coverage indicates participated in a round Chimeric Therapeutics raised.
Companies Chimeric Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Chimeric Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A profile of Chimeric Therapeutics and CEO Rebecca McQualter covering its CAR T cancer therapy, clinical progress, manufacturing partnerships, FDA designations, and path to Phase 2 trials by mid-2026.
Wholesale Investor's Steve Torso highlights Australian life sciences companies from the Emergence Preview Series, noting government grant funding, a Series A extension, venture co-investment, and a medtech company's ASX listing.
Also Wholesale Investor
Techboard's March 2022 roundup of Australian funding: megadeals by Immutable, Saluda Medical, Linktree and Zeller, many smaller raises, acquisitions, an IPO, several fund closes, and companies still seeking capital.
Also Australian FinTech